CL2014000432A1 - Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. - Google Patents

Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.

Info

Publication number
CL2014000432A1
CL2014000432A1 CL2014000432A CL2014000432A CL2014000432A1 CL 2014000432 A1 CL2014000432 A1 CL 2014000432A1 CL 2014000432 A CL2014000432 A CL 2014000432A CL 2014000432 A CL2014000432 A CL 2014000432A CL 2014000432 A1 CL2014000432 A1 CL 2014000432A1
Authority
CL
Chile
Prior art keywords
bacteriochlorophyll
sclera
chlorophyll
cornea
thinning
Prior art date
Application number
CL2014000432A
Other languages
English (en)
Inventor
Avigdor Scherz
Yoram Salomon
Arie Marcovich
Alexander Brandis
Daniel Wagner
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of CL2014000432A1 publication Critical patent/CL2014000432A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2014000432A 2011-08-23 2014-02-21 Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. CL2014000432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23

Publications (1)

Publication Number Publication Date
CL2014000432A1 true CL2014000432A1 (es) 2014-11-28

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000432A CL2014000432A1 (es) 2011-08-23 2014-02-21 Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.

Country Status (20)

Country Link
US (4) US9452172B2 (es)
EP (1) EP2747763B1 (es)
JP (1) JP6215203B2 (es)
KR (1) KR101962991B1 (es)
CN (1) CN103930108B (es)
AU (1) AU2012298156B2 (es)
BR (1) BR112014004306A2 (es)
CA (1) CA2846011C (es)
CL (1) CL2014000432A1 (es)
DK (1) DK2747763T3 (es)
ES (1) ES2856698T3 (es)
HK (1) HK1199412A1 (es)
HU (1) HUE053321T2 (es)
IN (1) IN2014CN02153A (es)
MX (1) MX360683B (es)
PE (1) PE20141183A1 (es)
PT (1) PT2747763T (es)
RU (1) RU2632439C2 (es)
WO (1) WO2013027222A1 (es)
ZA (1) ZA201402056B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2729180B1 (en) 2011-07-08 2019-01-23 The University of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
EP4420725A2 (en) 2012-03-29 2024-08-28 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
EP2830637B1 (en) 2012-03-29 2024-08-21 Epion Therapeutics, Inc. Compositions and methods for treating or preventing diseases associated with oxidative stress
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
JP6933377B2 (ja) 2015-07-21 2021-09-08 アヴェドロ・インコーポレーテッドAvedro,Inc. 光増感剤を用いた眼の処置用システム及び方法
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye
WO2017193019A1 (en) * 2016-05-05 2017-11-09 David Muller Corneal implant systems and methods
CN110167494A (zh) * 2017-01-03 2019-08-23 维特安公司 用于治疗视网膜脱离的方法和装置
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
US11702546B2 (en) 2018-10-24 2023-07-18 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
WO2020086697A1 (en) * 2018-10-24 2020-04-30 California Institute Of Technology Treatment of myopia and other ocular conditions using singlet oxygen
US20220041563A1 (en) * 2018-12-04 2022-02-10 Avedro, Inc. Compounds and Compositions for Eye Treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
EP1450790A4 (en) * 2001-10-03 2005-10-26 Miravant Pharm Inc PHOTOSENSIBILIZING CARBAMATE DERIVATIVES
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
ES2602204T3 (es) * 2004-06-07 2017-02-20 Yeda Research And Development Co., Ltd. Derivados de bacterioclorofila catiónicos y usos de los mismos
US20080138278A1 (en) * 2006-08-23 2008-06-12 Yeda Research & Development Co., Ltd. Conjugates of rgd peptides and porphyrin or (bacterio) chlorohyll photosynthesizers and their uses
KR101502632B1 (ko) 2006-10-24 2015-03-17 캘리포니아 인스티튜트 오브 테크놀로지 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
WO2011099602A1 (ja) * 2010-02-12 2011-08-18 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
ES2856698T3 (es) 2021-09-28
CA2846011C (en) 2019-10-15
PT2747763T (pt) 2021-02-22
WO2013027222A1 (en) 2013-02-28
MX360683B (es) 2018-11-13
RU2014110784A (ru) 2015-09-27
US20190231874A1 (en) 2019-08-01
EP2747763B1 (en) 2020-12-30
CN103930108A (zh) 2014-07-16
US9452172B2 (en) 2016-09-27
US20140378888A1 (en) 2014-12-25
IN2014CN02153A (es) 2015-05-29
US11058772B2 (en) 2021-07-13
PE20141183A1 (es) 2014-10-05
JP2014524465A (ja) 2014-09-22
CA2846011A1 (en) 2013-02-28
RU2632439C2 (ru) 2017-10-04
AU2012298156B2 (en) 2017-08-17
US20210330792A1 (en) 2021-10-28
EP2747763A1 (en) 2014-07-02
US20160354468A1 (en) 2016-12-08
KR101962991B1 (ko) 2019-03-27
DK2747763T3 (da) 2021-03-29
KR20140088514A (ko) 2014-07-10
ZA201402056B (en) 2015-11-25
CN103930108B (zh) 2017-05-24
BR112014004306A2 (pt) 2017-03-28
HK1199412A1 (en) 2015-07-03
AU2012298156A1 (en) 2014-04-10
MX2014002107A (es) 2015-04-16
JP6215203B2 (ja) 2017-10-18
HUE053321T2 (hu) 2021-06-28

Similar Documents

Publication Publication Date Title
CL2014000432A1 (es) Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201991484A1 (ru) Лекарственные формы энзалутамида
PL3399962T3 (pl) Kompozycja okulistyczna do leczenia choroby suchego oka
CR20170279A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CL2015000061A1 (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
CO6781507A2 (es) Novedosos derivados heterociclicos
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
NI201300070A (es) Ureas asimétricas y usos médicos de las mismas
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
DK3260865T3 (da) Fremgangsmåde til behandling af blod, blodprodukter og organer
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
ZA201703467B (en) Methods of treating ocular conditions
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112013009701A2 (pt) regimes de dosagem para o tratamento de doença vascular ocular